Michael J Rokoss, Koon K Teo
Index: Expert Opin. Pharmacother. 6(11) , 1911-9, (2005)
Full Text: HTML
Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardiovascular death, myocardial infarction, stroke, congestive heart failure, progressive renal impairment and onset of diabetes. Ramipril is usually dosed at 2.5-10 mg/day. Beneficial effects of ramipril are observed in the treatment of hypertension and congestive heart failure, prevention of cardiovascular events in high-risk patients, prevention of congestive heart failure, diabetes and other vascular events.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Ramipril
CAS:87333-19-5 |
C23H32N2O5 |
|
Clopidogrel bioactivation and risk of bleeding in patients c...
2014-12-01 [Clin. Pharmacol. Ther. 96(6) , 713-22, (2014)] |
|
[Telangiectasia during amlodipine therapy].
2013-03-01 [Ann. Dermatol. Venereol. 140(3) , 202-5, (2013)] |
|
Ramipril and hydrochlorothiazide treatment of hypertensive u...
2013-10-01 [Am. J. Emerg. Med. 31(10) , 1533-4, (2013)] |
|
Effect of zofenopril and ramipril on cardiovascular mortalit...
2013-07-01 [Am. J. Cardiol. 112(1) , 90-3, (2013)] |
|
Determination of ramipril in human plasma and its fragmentat...
2015-06-01 [Acta. Pharm. 65 , 159-69, (2015)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
